Echelon Wealth Partners Reiterates Buy Rating for IMV (NYSE:IMV)

Share on StockTwits

Echelon Wealth Partners reaffirmed their buy rating on shares of IMV (NYSE:IMV) in a research note released on Tuesday morning, AnalystRatings.com reports. Echelon Wealth Partners currently has a $12.25 price objective on the stock.

Several other research firms also recently weighed in on IMV. Zacks Investment Research downgraded shares of IMV from a buy rating to a hold rating in a research report on Saturday, October 26th. HC Wainwright reiterated a buy rating and issued a $11.50 price target on shares of IMV in a research report on Monday, November 11th. Wells Fargo & Co initiated coverage on shares of IMV in a research report on Monday, October 28th. They issued a market perform rating on the stock. Finally, Raymond James set a $10.00 price target on shares of IMV and gave the stock an outperform rating in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $9.60.

IMV traded up $0.08 during trading on Tuesday, hitting $2.49. The company’s stock had a trading volume of 5,792 shares, compared to its average volume of 19,652. IMV has a one year low of $2.25 and a one year high of $7.07. The business’s 50 day simple moving average is $2.66 and its 200-day simple moving average is $3.12.

IMV (NYSE:IMV) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.03). The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.05 million.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMV. Citadel Advisors LLC bought a new position in IMV in the second quarter worth approximately $37,000. Hartford Financial Management Inc. increased its stake in shares of IMV by 9.6% in the third quarter. Hartford Financial Management Inc. now owns 38,098 shares of the company’s stock worth $94,000 after purchasing an additional 3,348 shares in the last quarter. Bank of Montreal Can increased its stake in shares of IMV by 17.5% in the second quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock worth $260,000 after purchasing an additional 13,228 shares in the last quarter. Morgan Stanley increased its stake in shares of IMV by 260.5% in the second quarter. Morgan Stanley now owns 90,368 shares of the company’s stock worth $264,000 after purchasing an additional 65,300 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in shares of IMV by 3.6% in the second quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock worth $288,000 after purchasing an additional 3,453 shares in the last quarter.

IMV Company Profile

IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

Further Reading: Monthly Dividend Stocks Can Provide Solid Income

Analyst Recommendations for IMV (NYSE:IMV)

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Ardelyx Inc  Given Consensus Rating of “Hold” by Analysts
Ardelyx Inc Given Consensus Rating of “Hold” by Analysts
Western Midstream Partners LP  Receives $32.25 Consensus Price Target from Analysts
Western Midstream Partners LP Receives $32.25 Consensus Price Target from Analysts
SL Green Realty Corp  Receives $93.85 Average Price Target from Brokerages
SL Green Realty Corp Receives $93.85 Average Price Target from Brokerages
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
Analysts Set SS&C Technologies Holdings, Inc.  Price Target at $65.91
Analysts Set SS&C Technologies Holdings, Inc. Price Target at $65.91


© 2006-2019 Ticker Report